Edward A Kesicki

This inventor holds 45 USPTO granted patents and 11 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Quinazolinone Inhibitors. Top assignees: Icos Corporation, Prolinx Incorporated, Algomedix, Inc.. Active years: 2000-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Edward A Kesicki. Retrieved from https://idiyas.com/inventor/edward-a-kesicki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 45 (Patent Applications = 11)

% Patents Active = 57.8

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 8)

Average Co-Inventor Count = 5.9

ph-index = 19

Forward Citations = 1,415(Granted Patents)

Location History:

Seattle, WA (US) (2014)
Bothwell, WA (US) (2015)
Mill Creek, WA (US) (2019)
Bothell, WA (US) (2000 - 2021)

Company Filing History:

Luitpold Pharmaceuticals, Inc.

6. 3 out of 834,513

Other

patents

Years Active: 2000-2021

Loading Chart...

Areas of Expertise:

Quinazolinones

Phosphatidylinositol 3-Kinase Delta

TRPA1 Modulators

Tetracycline Derivatives

Cancer Treatment

Cyclic AMP Inhibitors

CHK1 Inhibitors

Neuroprotective Benefits

Heteroaryl Urea Derivatives

Xanthones

Thioxanthones

Acridinones

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10906907 - Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof (2021-02-02),

2. 10695349 - Inhibitors of human phosphatidylinositol 3-kinase delta (2020-06-30),

3. 10428049 - TRPA1 modulators (2019-10-01),

4. 10398695 - Inhibitors of human phosphatidylinositol 3-kinase delta (2019-09-03),

5. 10336756 - (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta (2019-07-02),

6. 10010550 - Inhibitors of human phosphatidylinositol 3-kinase delta (2018-07-03),

7. 9951046 - TRPA1 modulators (2018-04-24),

8. 9896422 - Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits (2018-02-20),

9. 9573912 - Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits (2017-02-21),

10. 9487772 - Inhibitors of human phosphatidylinositol 3-kinase delta (2016-11-08),

11. 9168265 - Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits (2015-10-27),

12. 9149477 - 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta (2015-10-06),

13. 8993583 - 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta (2015-03-31),

14. 8980901 - 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta (2015-03-17),

15. 8779131 - 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta (2014-07-15),

Title: The Innovative Journey of Edward A Kesicki

Introduction:

Edward A Kesicki, a talented inventor based in Bothell, WA, has made significant contributions to the field of technology through his creative and groundbreaking ideas.

Latest Patents:

Edward A Kesicki holds several patents in various technological domains, showcasing his versatility and ingenuity in inventing new solutions to complex problems.

Career Highlights:

Throughout his career, Edward A Kesicki has demonstrated a keen ability to identify gaps in the market and develop innovative products to address them. His passion for technology and commitment to excellence have earned him a reputation as a visionary inventor.

Collaborations:

Edward A Kesicki has collaborated with leading tech companies and research institutions to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion:

In conclusion, Edward A Kesicki's relentless pursuit of innovation and his dedication to pushing the boundaries of technology make him a standout figure in the world of inventors. His contributions have not only transformed industries but have also inspired the next generation of innovators to dream big and think outside the box.

Profile summary based on public USPTO records.